Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways

Purinergic Signalling

Volumn 5, Issue 1, 2009, Pages 117-125

  García Echeverría, Carlos ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cancer; Drug design; Kinase; MEK; PI3K; Raf; Targeted therapy

Indexed keywords

EID: 60449094950     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-008-9111-5     Document Type: Review

References (44)

1. Wang JW, Wilcoxen KM, Nomoto K, Wu S (2007) Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem 7:1364-1378
2. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310
3. Wan PT, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867
4. Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313-319
5. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene is human cancer. Nature 417:949-954
6. Li N, Batt D, Wartmuth M (2007) B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs 8:452-456
7. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
8. Nagar B, Bormmann WG, Pellicena P et al (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236-4243
9. Schindler T, Bornmann W, Pellicena P et al (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289(5486):1938-1942
10. Pargellis C, Tong L, Churchill L et al (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9:268-272
11. Amiri P, Aikawa ME, Dove J et al (2006) CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations (abstract 4855). Proc Am Assoc Cancer Res 47
12. Ohren JF, Chen H, Pavlovsky A et al (2004) Structures of human MAP kinase I (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11:1192-1197
13. Sebolt-Leopold JS, Dudley DT, Herrera R et al (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5(7):810-816
14. Herrera R, Sebolt-Leopold JS (2002) Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 8(4):S27-S31
15. Rinehart J, Adjei AA, Lorusso PM et al (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040 in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462
16. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937-947
17. Spicer JA, Rewcastle GW, Kaufman MD et al (2007) 4-anilino-5-caboxamide-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase. J Med Chem 50:5090-5102
18. Zhang N, Wu B, Eudy N et al (2001) MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines. Bioorg Med Chem Lett 11:1407-1410
19. Zhao A, Lee SH, Mojena M et al (1999) Resorcyclic acid lactones: naturally occurring potent and selective inhibitors of MEK. J Antioiot (Tokyo) 52:1086-1094
20. Garcia-Echeverria C (2007) Survival signaling. Top Med Chem 1:169-206
21. Stauffer F, Holzer P, Garcia-Echeverria C (2005) Blocking the PI3K/PKB pathway in tumor cells. Curr Med Chem Anticancer Agents 5:449-462
22. Maira SM, Voliva C, Garcia-Echeverria C (2008) Class IA phosphatidylinositol 3-kinase: From their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets 12:223-238
23. Brian PW, Hemming HG, Norris GLF (1957) Wortmannin, an antibiotic produced by Penicillium wortmanni. Br Mycol Soc Trans 40:365-368
24. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248
25. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ et al (1996) Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 16:1722-1733
26. Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105
27. Yu K, Lucas J, Zhu T et al (2005) PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther 4:538-545
28. Ihle NT, Paine-Murrieta G, Berggren MI et al (2005) The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 4:1349-1357
29. Ihle NT, Williams R, Chow S et al (2004) Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 3:763-772
30. Garlich JR, De P, Dey N et al (2008) A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68:206-215
31. Stauffer F, Garcia-Echeverria C, Furet P et al (2007) Medicinal chemistry efforts towards the identification and development of inhibitors of phosphatidylinositol 3-kinase (PI3Ks) and related kinases for cancer treatment (abstract 3953). Proc Am Assoc Cancer Res
32. Maira SM (2007) Biochemical, cellular and in vivo profiling of a new PI3K inhibitor from the imidazoquinoline series (oral presentation). Proc Am Assoc Cancer Res
33. Foster PG (2007) Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147 (abstract C199). EORTC Meeting
34. Shapiro GI, Edelman G, Calvo E et al (2007) Targeting aberrant PI3K pathway signaling with XL147, a potent, selective, and orally bioavailable PI3K inhibitor (abstract C205). EORTC Meeting
35. Laird D (2007) XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR (abstract B250). EORTC Meeting
36. Patnaik A, Lorusso PM, Tabernero J et al (2007) Biomarker development for XL765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administered to patients in a phase I clinical trial (abstract B265). EORTC Meeting
37. Raynaud FI, Eccles S, Clarke PA et al (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67:5840-5850
38. Fan QW, Cheng CK, Nicolaodes TP et al (2007) A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67:7960-7965
39. Walker EH, Pacold ME, Perisic O et al (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6:909-919
40. Walker EH, Perisic O, Ried C et al (2000) Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402:313-320
41. Huang CH, Mandelker D, Schmidt-Kittler O et al (2007) The structure of a human p110α/p85 α complex elucidates the effects of oncogenic PI3K α mutations. Science 318:1744-1748
42. Knight ZA, Chiang GG, Alaimo PJ et al (2004) Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 12:4749-4759
43. Redaelli A, Lee JM, Stephens JM, Pashos CL (2003) Epidemiology and clinical burden of acute myeloid leukemia. Expert Rev Anticancer Ther 3:695-710
44. Knight ZA, Gonzalez B, Feldman ME et al (2006) Pharmacological map of the PI3K family defines a role for p110α in insulin signaling. Cell 125:733-747